Crossbow Therapeutics
TCR-mimetic, AML, MDS, CMML, CML
Crossbow Therapeutics
Cambridge, MA
United States
TAP Partner
Crossbow Therapeutics is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets.
Program Name(s)
Therapy Acceleration Program
Project Title
A phase 1 study of CBX-250, a TCR-mimetic antibody, in patients with AML, MDS or CMML
Coleman Lindsley
AML/MDS
Coleman Lindsley, MD PhD
Boston, MA
United States
Dana-Farber Cancer Institute
Dr. Lindsley is an Assistant Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute. He received his M.D. and Ph.D. in Immunology from Washington University School of Medicine, then completed a residency in internal medicine at Brigham and Women’s Hospital and a fellowship in oncology at the Dana-Farber Cancer Institute. He is a member of the MDS Genetics Subcommittee for the NIH National MDS Study, NHLBI Trans-Omics for Precision Medicine Steering Committee, and the International Working Group for Prognosis in MDS (IWG-PM) molecular committee. The primary focus of his laboratory is the biology and treatment of myeloid malignancies. His genetic studies have led to new genomic models of leukemia classification and MDS outcome after stem cell transplantation. His laboratory uses mouse and cell line models to dissect the mechanistic basis of genetic cooperation during myeloid disease progression, with a specific focus on leukemia initiation in patients with predisposition syndromes and mutations that cause epigenetic alterations.
Program Name(s)
Career Development Program
Project Title
Genetic pathways of myeloid transformation and treatment response
Lawrence Boise
CART and myeloma
Lawrence Boise, PhD
Atlanta, GA
United States
Emory University
Lawrence Boise, PhD is the R. Randall Rollins Chair of Oncology and Professor in the Department of Hematology and Medical Oncology in the Emory University School of Medicine. Dr. Boise also serves as the Associate Director of Education and Training in the Winship Cancer Institute of Emory University. He received his PhD from VCU-Medicine and did his postdoctoral training at the University of Michigan and the University of Chicago. Dr. Boise took his first faculty position at the University of Miami in 1996 and rose to the rank of Professor before moving to Emory in 2009. Dr. Boise was involved in early studies to identify genes that control cell survival and cell death and has been studying these processes to better understand how to improve our treatment of cancer, particularly the plasma cell malignancy multiple myeloma. Dr. Boise serves as a Senior Editor at Molecular Cancer Research and is on the editorial board of Blood Cancer Discovery.
Program Name(s)
Discovery
Project Title
Caroline Arber
myeloma CAR-T
Caroline Arber, MD
Lausanne,
Switzerland
Centre Hospitalier Universitaire Vaudois
Caroline Arber obtained her Doctor of Medicine from the University of Basel, Switzerland, and specialized in Internal Medicine and Hematology, with a focus on hematologic malignancies and stem cell transplant. To dive into the T cell engineering field, she moved to the Center for Cell and Gene Therapy, Baylor College of Medicine, USA, where she was a research fellow (2010-2014) and an Assistant Professor (2014-2017). Since 2017 she is an Associate Professor, Research Group leader and Attending Physician at the Lausanne University Hospital, University of Lausanne and Ludwig Institute for Cancer Research Lausanne, Switzerland. She leads a translational research group investigating novel T cell engineering strategies for hematologic malignancies. She also studies the impact of the bone marrow immune microenvironment on outcomes of CAR T cell therapies in myeloma. She has published several last author papers in journals such as Blood, JITC, Cancer Immunology Research, Science Advances.
Program Name(s)
Translational Research Program
Project Title
Designed biosensor to enhance CAR T cell therapy for multiple myeloma
Adam de Smith
pediatric ALL and Down Syndrome
Adam de Smith, PhD
Los Angeles, CA
United States
University of Southern California
I am a genetic epidemiologist and Assistant Professor in the Center for Genetic Epidemiology and Department of Population and Public Health Sciences at the USC Keck School of Medicine. During my PhD, my research was focused on genetic variation and its role in human disease, and I received training in genetic epidemiology. Keen to pursue a career in childhood cancer research, I obtained a postdoctoral position at UCSF studying the etiology of acute lymphoblastic leukemia (ALL), the most common childhood cancer. In 2018, I started a faculty position at USC, where I lead epidemiology studies of ALL in high-risk populations, including Hispanic/Latinos and children with Down syndrome. My research has led to several novel discoveries, identifying new genetic risk factors for ALL and shedding light on how Down syndrome increases leukemia risk. Understanding the causes of childhood ALL is my life’s work, with the hope that our discoveries will help to develop precision prevention strategies.
Program Name(s)
Career Development Program
Project Title
Pooja Khandelwal
bone marrow transplantation
Pooja Khandelwal, MD
Cincinnati, OH
United States
Cincinnati Children’s Hospital Medical Center
I am a pediatric oncologist and associate professor in the division of bone marrow transplantation at Cincinnati Children’s Hospital Medical Center. I have a clinical and research interest in graft versus host disease because this is the most significant, devastating and life-impacting complication after a bone marrow transplant. I led the study in children of high dose oral vitamin A and showed that when given before starting chemotherapy, vitamin A reduces acute gastrointestinal and chronic graft versus host disease. I am now collaborating with 3 adult BMT programs to try and validate my findings in adult BMT patients as adults tend to have more chronic GVHD than children and I would like to extend this easy and effective strategy to patients of all ages across the US and worldwide.
Program Name(s)
Academic Clinical Trials Program (ACT)
Project Title
A randomized clinical trial of oral vitamin A to reduce chronic graft versus host disease in BMT
Lori Muffly
Equity in Access
Lori Muffly, MD
Palo Alto, CA
United States
Stanford University
Dr. Lori Muffly MD MS is an Associate Professor of Medicine at Stanford University in the Division of Blood and Marrow Transplantation and Cellular Therapy. Dr. Muffly is a clinician and clinical investigator whose research includes both health outcomes and clinical trials pertaining to adults with acute leukemia. Her clinical practice serves adults across Northern California with advanced acute leukemias who require hematopoietic cell transplantation and other cellular immunotherapies. She has a specific research interest in improving access to specialty cancer care and reducing health disparities in young adults with acute lymphoblastic leukemia and has published extensively on these topics. She also serves as the PI of multiple investigator-initiated health outcomes studies and clinical trials, including studies evaluating measurable residual disease in adult acute lymphoblastic leukemia, novel chimeric antigen receptor T cell studies for acute leukemia, and she leads a recently established real world consortium investigating outcomes following cellular therapies administered to adults with acute lymphoblastic leukemia. Dr. Muffly has successfully collaborated with Drs. Parsons and Keegan on several previous studies and publications related to adolescent and young adult leukemia and access to cancer care and has delivered numerous national talks on the subject.
Program Name(s)
Equity in Access
Project Title
Francesca Del Bufalo
Pediatric Trial
Francesca Del Bufalo, MD, PhD
Rome,
Italy
Ospedale Pediatrico Bambino Gesù
Dr. Del Bufalo is a physician-scientist with interest in childhood malignancies, tumor immunology, immunotherapy and hematopoietic stem cell transplantation. She participated in the preclinical and clinical development of the academic clinical trials with CAR-T cells at OPBG. In particular, she coordinated 2 studies on different CD9-CAR T cell platforms for the treatment of children with relapsed/refractory (r/r) BCP-ALL and the phase I/II study to test GD2-CART01 in children with r/r neuroblastoma. She is the PI of a research project to test donor-derived CAR T cells for the treatment of children/young adults with BCP-ALL. She managed the activation and conduction of the phase I clinical trial on CD7-CART.PEBL for the treatment of children/young adults with r/r T-ALL (PI Prof. Franco Locatelli). She is the new chair of the European iBFM Resistant Disease Committee and President of the Young Investigators Section of the scientific technical committee of the Italian Ministry of Health.
Program Name(s)
Academic Clinical Trials Program (ACT)
Project Title
CD7-CAR T cells with PEBL for treatment of children/young adults with relapsed/refractory T-ALL